The primary objective of this trial is to assess the efficacy of infliximab therapy 5mgkg by body weight compared with methotrexate in adult subjects aged 18-75 years diagnosed with moderate to severe plaque-type psoriasis for at least 6 months prior to study screening subjects with concurrent psoriatic arthritis may also be enrolled
Data and Resources
- An Open-Label Randomized Efficacy and Safety Study of Infliximab Versus Methotrexate in the Treatment of Moderate to Severe Psoriasisjson
The primary objective of this trial is to assess the efficacy of infliximab...
|Release Date|| |
|Public Access Level|| |